TP53 and acute myeloid leukemia: Seipel et al. analyzed the in vitro efficacy of MDM2 inhibitor NVP-HDM201 in combination with Midostaurin, demonstrating significantly increased susceptibility to FLT3i in NPM1 and TP53 wild type FLT3mut AML cells with high allelic ratio.